Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a first of its kind study into the population and spread of tuberculosis-causing (TB) bacteria in Ho Chi Minh City, Thuong Thuong Nguyn and collegues at OUCRU Vietnam, Australia, UK and Singapore have found that more than half of cases can be attributed to one particular strain of the bacteria.

TB  MDR-TB  TB/HIV

Using state-of-the-art genomics technology, a Melbourne-led international collaboration, including researchers from OUCRU in Vietnam and Singapore, sequenced the DNA from bacteria isolated from the lungs of 1635 TB patients located in outpatient clinics in eight districts of Ho Chi Minh City. The findings, published in Nature Genetics this week, concluded that the strain of TB-causing bacteria known as the Beijing lineage, was responsible for 59 per cent of infections, and even more (75%) of those diagnosed in younger people.

TB is the leading cause of death globally from a single infectious agent – Mycobacterium tuberculosis – that typically affects the lungs, but can also infect other sites of the body. Multiple antibiotics are used to treat TB, however treatment is long (six months), and the emergence of drug-resistant bacteria is a considerable threat to global health.

Vietnam is one of the WHO High Burden Countries for TB and multi drug-resistant TB, and in 2016 there were an estimated 126,000 cases and 13,850 deaths in the South East Asian country. Co-lead Investigator of the study and a Senior Research Fellow, Dr Sarah Dunstan from the Peter Doherty Institute for Infection and Immunity (a joint venture of The University of Melbourne and The Royal Melbourne Hospital), said within the Beijing lineage they found a mutation, which likely bolsters the bacteria’s ability to spread. “Combating and managing TB spread requires new strategies to diagnose, treat and protect against emerging and evolving strains of the bacteria,” said Dr Dunstan. “Armed with an understanding of how the disease is spread in Ho Chi Minh City could allow more targeted local TB control, and this knowledge could potentially be applied to other settings given the Beijing lineage is found worldwide, predominantly in Asia.”

First author on the paper describing the study, Associate Professor Kathryn Holt from the University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute, said the study shows the Beijing lineage of TB bacteria spreads more easily from person-to-person than other strains of the bacteria. “Contact tracing – looking for early signs of TB infection in people who have been in close contact with TB patients, and treating them before they can spread the disease further – is an important part of TB control, but it takes a lot of resources,” said Associate Professor Holt. “All TB patients have the potential to transmit the TB bacteria to others when they cough, but our data indicates this is more likely to result in new disease cases if the infection is caused by the Beijing lineage. So if resources are limited, it would make sense to prioritise contact tracing for Beijing lineage TB cases.”

Co-author Dr Nguyen T. T. Thuong, head of OUCRU’s TB group in Ho Chi Minh City, comments: “TB treatment fails in many patients infected with multidrug resistant strains, which are then passed on, increasing the number of resistant cases in the community. My team in Vietnam now is running a pilot study in early diagnosis of drug resistant TB cases using whole genome sequencing. The findings from this publication can be applied concurrently to identify those carrying the easily-spread-mutation. If this test becomes a bedside diagnostic tool, it will allow not only early diagnosis of drug resistance and more precise treatment but also better management against disease transmission.”

The study was funded by the National Health and Medical Research Council in Australia, Wellcome Trust UK and A*STAR Biomedical Research Council Singapore.

Similar stories

World’s largest clinical trial for COVID-19 treatments expands internationally

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

OCGHR Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

OCGHR Research

Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

OCGHR Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.